UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 22, 2004
PHARMACOPEIA, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
0-27188 |
|
33-0557266 |
|
(State or other
jurisdiction of |
|
(Commission |
|
(I.R.S. Employer |
|
|
|
|
|
|
|
PO Box 5350, Princeton, New Jersey |
|
08543-5350 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
(609) 452-3600
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Item 9. REGULATION FD DISCLOSURE
On April 22 and April 23, 2004, Pharmacopeia, Inc. expects to make presentations concerning its business to certain investors. The materials to be utilized during the presentations are attached as Exhibit 99.1 to this report.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 9 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PHARMACOPEIA, INC. |
||
|
|
|
||
|
|
|
||
|
|
By: |
/s/ John J. Hanlon |
|
|
|
|
||
|
|
|
||
|
|
John J. Hanlon, Executive Vice President and |
||
|
|
Chief Financial Officer |
||
|
|
|
||
|
|
|
||
|
Date: April 22, 2004 |
|
||
2